Skip to main content
Clinical Trials/NCT03093220
NCT03093220
Unknown
Not Applicable

Molecular Typing of Adult Community-acquired Pneumonia in China

Peking University People's Hospital1 site in 1 country500 target enrollmentMarch 2017

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Respiratory Infections
Sponsor
Peking University People's Hospital
Enrollment
500
Locations
1
Primary Endpoint
30 day mortality
Last Updated
9 years ago

Overview

Brief Summary

Community-acquired pneumonia (CAP) is a heterogeneous disease causing great morbidity, mortality and health care burden globally. Typing methods for discriminating different clinical conditions of the same disease are essential to a better management of CAP. Traditional typing systems based separately on clinical manifestations (such as PSI and CURB-65), pathogens(bacterial types, virulence, drug resistance, etc) or host immune state (immunocompetent, immunocompromised or immunodeficiency). Thus, they are barely able to represent the real disease status nor to precisely predict the mortality.

As the development of multi-omic technologies, the relatedness of different phenotypes at a molecular level have revolutionized our ability to differentiate among patients. Our study is aimed at establishing a novel molecular typing method of CAP. Multi-omic (including genomics, transcriptomes, and metabolisms) data obtained from enrolled CAP patients and isolated pathogens would be integrated analyzed and interpreted. Tthe investigators believe that an appropriate molecular typing method would lead to revolutionary changes in current arrangements of CAP.

Registry
clinicaltrials.gov
Start Date
March 2017
End Date
December 2018
Last Updated
9 years ago
Study Type
Observational
Sex
All

Investigators

Responsible Party
Sponsor

Eligibility Criteria

Inclusion Criteria

  • adult (aged \> 16 years)
  • diagnosed as community-acquired pneumonia

Exclusion Criteria

  • being immunocompromised, including history of glucocorticoid taken for more than 1 month, history of immunosuppressive therapy, history of human immunodeficiency virus (HIV) infection, solid tumor or hematological malignancy
  • history of long-term nursing home stays
  • history of recently hospitalized (\<90 days)

Outcomes

Primary Outcomes

30 day mortality

Time Frame: 30 days after the onset of CAP

all-cause death in 30 days after the onset of CAP

Secondary Outcomes

  • complications(30 days after the onset of CAP)

Study Sites (1)

Loading locations...

Similar Trials